BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

GeneDx (NASDAQ:WGS) shares maintained their ground following a reiteration of a Hold rating and a $75.00 price target by Jefferies analysts. According to InvestingPro data, analyst targets for the ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...

Das GeneDx-Management bestätigte, dass das Unternehmen kein "Code Stacking" betreibt und angemessene CPT-Codes für Genom- und Exom-Tests abrechnet, die das Kerngeschäft darstellen. Die Analysten hoben ...

Eine Analyse von InvestingPro zeigt, dass das Unternehmen mit einem gesunden Verhältnis von kurzfristigen Vermögenswerten zu kurzfristigen Verbindlichkeiten von 2,41 eine starke Fähigkeit zur ...

“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...

Management expects GeneDx to report: Revenues of at least $299M for full year 2024, an increase of 54% year-over-year vs previous guidance was $284-$290M. Consensus $288.2M..

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...